Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00357253
Other study ID # CDR0000484429
Secondary ID U01CA081457PBTC-
Status Completed
Phase Phase 1
First received July 26, 2006
Last updated January 8, 2013
Start date January 2006
Est. completion date March 2010

Study information

Verified date January 2013
Source Pediatric Brain Tumor Consortium
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Capecitabine may make tumor cells more sensitive to radiation therapy. Giving capecitabine together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with radiation therapy in treating young patients with newly diagnosed, nonmetastatic brain stem glioma or high-grade glioma.


Description:

OBJECTIVES:

Primary

- Estimate the maximum tolerated dose of capecitabine rapidly disintegrating tablets (RDT) administered concurrently with radiotherapy in young patients with newly diagnosed, nondisseminated intrinsic brain stem glioma or high-grade glioma.

- Describe the dose-limiting toxicity in patients treated with this regimen.

Secondary

- Describe the safety profile of this regimen.

- Characterize the pharmacokinetics of capecitabine RDT in these patients.

- Explore the exposure-response relationship for measures of safety and effectiveness using pharmacokinetic and pharmacodynamic models.

- Describe the antitumor activity of this regimen observed in these patients.

- Estimate distributions of progression-free survival and survival in patients treated with this regimen.

- Characterize radiographic changes in tumor, using MRI, perfusion and diffusion MRI, and positron emission tomography (PET) scans, in patients treated with this regimen.

OUTLINE: This a multicenter, dose-escalation study of capecitabine rapidly disintegrating tablets (RDT).

Patients undergo radiotherapy once daily, 5 days a week, for approximately 6 weeks. Beginning within 24 hours of starting radiotherapy, patients also receive oral capecitabine RDT twice daily on days 1-21. Treatment with capecitabine RDT repeats every 21 days for 3 courses.

Cohorts of 3-6 patients receive escalating doses of capecitabine RDT until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Beginning in week 12, patients receive capecitabine RDT at a fixed dose twice daily on days 1-14. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection periodically during course 1 for pharmacokinetic correlative studies. Patients also undergo MRI, and rapid perfusion/diffusion MRI at baseline and periodically during study for radiographic correlative studies.

After completion of study treatment, patients are followed periodically for 2 years.

PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 3 Years to 21 Years
Eligibility DISEASE CHARACTERISTICS:

- One of the following newly diagnosed, nondisseminated brain tumors:

- Intrinsic infiltrating brain stem glioma

- Histopathologic diagnosis not required

- Histopathologically confirmed high-grade glioma, meeting all of the following criteria:

- Underwent prior definitive surgery = 28 days ago with incompletely resected disease

- Any of the following subtypes allowed:

- Anaplastic astrocytoma

- Glioblastoma multiforme

- Other high-grade glioma

- No anaplastic oligodendroglioma

PATIENT CHARACTERISTICS:

- Karnofsky performance scale (PS) 50-100% (if > 16 years of age) or Lansky PS 50-100% (if = 16 years of age)

- Absolute neutrophil count = 1,000/mm³

- Platelet count = 100,000/mm³ (transfusion independent)

- Hemoglobin = 8 g/dL (transfusion independent)

- Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min OR creatinine based on age as follows:

- No more than 0.8 mg/dL (for patients 5 years of age and under)

- No more than 1 mg/dL (for patients 6-10 years of age)

- No more than 1.2 mg/dL (for patients 11-15 years of age)

- No more than 1.5 mg/dL (for patients over 15 years of age)

- Bilirubin = 1.5 times upper limit of normal (ULN)

- ALT = 5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No uncontrolled infection

- No significant cardiac, hepatic, gastrointestinal, renal, pulmonary, or other systemic disease

- No known hypersensitivity to capecitabine or any of its components

- No known dihydropyrimidine dehydrogenase (DPD) deficiency

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Prior dexamethasone and/or surgery allowed

- No prior chemotherapy, radiotherapy, immunotherapy, or bone marrow transplantation

- No other concurrent anticancer or experimental drug therapies or agents

- No concurrent warfarin or sorivudine or its chemically related analogues (e.g., brivudine)

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
capecitabine
This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
Radiation:
radiation therapy
Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.

Locations

Country Name City State
United States Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda Maryland
United States Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston Massachusetts
United States Children's Memorial Hospital - Chicago Chicago Illinois
United States Duke Comprehensive Cancer Center Durham North Carolina
United States Dan L. Duncan Cancer Center at Baylor College of Medicine Houston Texas
United States Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital Houston Texas
United States St. Jude Children's Research Hospital Memphis Tennessee
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States Children's Hospital and Regional Medical Center - Seattle Seattle Washington
United States Children's National Medical Center Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Pediatric Brain Tumor Consortium National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of capecitabine rapidly disintegrating tablets (RDT) in combination with radiotherapy First 11 weeks of therapy Yes
Primary Dose-limiting toxicity First 11 weeks of therapy Yes
Secondary Pharmacokinetics of capecitabine RDT measured periodically during course 1 Day 1 and Day 14 of therapy No
Secondary Tumor response Brain imaging to assess tumor response to the treatment is performed at baseline, week 11, end of course 6, and then every 3 months for two years. From day 1 of treatment until off study No
Secondary Survival From initiation of treatment until death or off study No
Secondary Radiographic changes in gliomas as measured by MRI, magnetic resonance spectroscopy (MRS), perfusion and diffusion MRI Baseline, week 11, then every 3 months for 2 years or until off study No
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Completed NCT00003484 - Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Phase 1